Gene Therapy

Every disease with a genetic component carries, somewhere in its molecular pathology, a correction that is in principle possible — a misfolded protein that could be properly folded if the encoding sequence were right, a missing enzyme that could be restored, a mutant allele that could be silenced or replaced. Gene therapy is the discipline attempting to realise that potential clinically: to treat disease not by managing its downstream consequences with drugs, but by correcting or compensating for the molecular defect at its root. The idea is as old as molecular biology itself. Its execution has been far harder, more dangerous, and more technically complex than the original concept suggested — and the journey from the first gene therapy experiments in the early 1990s through the catastrophic setbacks of the late 1990s and early 2000s to the current era of multiple approved therapies for rare genetic diseases, CRISPR-based medicines, and RNA therapeutics has been one of the most eventful chapters in the history of medicine. This guide covers that journey — the vectors, the strategies, the science, the safety record, and the profound questions about what genetic medicine means for how humans will relate to heritable disease in future generations.

Gene Therapy — Definition, Scope, and the Four Therapeutic Strategies

Gene therapy encompasses any intervention that treats, prevents, or potentially cures disease by introducing, altering, or removing genetic material within a patient’s cells. Regulatory definitions vary slightly between jurisdictions — the FDA defines gene therapies as products that mediate their effects by transcription or translation of transferred genetic material, or by integrating into the host genome — but the clinical scope is broad: from delivering a functional copy of a defective gene to precisely editing a disease-causing mutation to silencing a harmful gene at the RNA level to engineering immune cells to recognise and kill tumours.

Historical Milestones and Setbacks — A Field Built on Hard Lessons

The history of gene therapy is not a linear progression from idea to clinic. It is a narrative defined as much by its failures — some of them catastrophic — as by its successes, and the safety and regulatory frameworks that govern the field today exist precisely because of what went wrong in the 1990s and early 2000s. Understanding this history is not merely academic context; it explains why specific vectors are preferred, why regulatory requirements are structured as they are, and why the field’s current optimism is tempered by careful attention to long-term safety.

Viral Delivery Vectors — Co-opting Viral Biology for Therapeutic Purposes

Viruses have spent hundreds of millions of years evolving sophisticated mechanisms to deliver genetic material into cells — penetrating cellular membranes, evading intracellular degradation, and navigating their nucleic acid cargo to the appropriate intracellular compartment. Gene therapy co-opts this evolved delivery machinery by replacing viral genes responsible for pathogenicity and replication with therapeutic sequences, retaining only the structural and functional elements needed for cell entry and cargo delivery. The choice of vector is one of the most consequential decisions in gene therapy design, as it determines tissue tropism, payload capacity, integration behaviour, immunogenicity, and manufacturing complexity.

Adeno-Associated Virus — The Dominant Platform for In Vivo Gene Therapy

Adeno-associated viruses are small, non-enveloped, single-stranded DNA viruses that have no known pathogenicity in humans — they were first discovered as contaminants in adenovirus preparations and require a helper virus for productive replication. These properties — natural non-pathogenicity, small size facilitating manufacturing, and the ability to transduce both dividing and post-mitotic cells — combined with the development of recombinant AAV (rAAV) production systems, have made AAV the dominant platform for in vivo gene therapy in the current era.

AAV SEROTYPE   PRIMARY TISSUE TROPISM              CLINICAL APPLICATION EXAMPLES

AAV1          Muscle, heart, CNS, liver             Glybera (LPL deficiency — historical)
AAV2          Muscle, liver, eye, CNS               Luxturna (subretinal injection, RPE65)
AAV5          Liver, CNS, lung, eye                 Roctavian (haemophilia A, hepatic)
AAV8          Liver (highly efficient), heart, eye  Liver-directed gene therapy trials
AAV9          CNS, motor neurons, heart, liver      Zolgensma (SMA — IV or intrathecal)
AAVrh10      CNS, heart, liver                     Neurological disease trials
AAV3B        Liver (human hepatocyte-specific)     BioMarin haemophilia A programme
AAVe5/LK03  Liver                                 Hemgenix (haemophilia B — Factor IX)
AAVrh74      Skeletal muscle                       Elevidys (Duchenne muscular dystrophy)

ENGINEERED VARIANTS:
  AAV-PHP.B/PHP.eB: enhanced CNS penetration after IV delivery (murine > human)
  AAV-SCH9:         high liver transduction, reduced pre-existing immunity prevalence
  AAVanc80:         ancestral reconstruction — novel capsid with broad tropism

KEY LIMITATION:
  Packaging capacity ~4.7 kb — insufficient for large genes (e.g., dystrophin 11.1 kb,
  CFTR 4.7 kb with regulatory elements). Strategies: dual-vector, micro-genes,
  or alternative vectors for large-gene targets.

AAV vectors administered at therapeutic doses are largely episomal in post-mitotic tissues — they do not efficiently integrate into the host genome in the way lentiviral vectors do. The therapeutic DNA is maintained as circular episomal concatemers in the nucleus, providing durable expression in non-dividing cells (liver hepatocytes, muscle fibres, neurons, retinal pigment epithelium) that can persist for years to decades. This episomal persistence is a major safety advantage over integrating vectors, but it also means that in rapidly dividing tissues — including the dividing hepatocytes of children’s growing livers — the episomal vector is diluted with each cell division, and long-term expression declines. This is why age at treatment is a critical variable in AAV gene therapy: Zolgensma (SMA type 1) is most effective when given in the first weeks of life before motor neuron degeneration advances; Luxturna provides lasting benefit in the post-mitotic retinal pigment epithelium regardless of patient age.

Non-Viral Delivery Systems — Vectors Without a Virus

Viral vectors’ immunogenicity, manufacturing complexity, payload size limits, and re-dosing constraints have driven sustained interest in non-viral alternatives — synthetic or semi-synthetic delivery systems that can package and protect nucleic acid cargoes, facilitate cell entry, and release their payload intracellularly without invoking anti-viral immune responses. Non-viral vectors are less efficient than their viral counterparts at transducing specific cell types, but they offer important advantages: large payload capacity, no pre-existing immunity, repeated dosing potential, lower manufacturing cost, and a safety profile free from viral integration risk.

In Vivo and Ex Vivo Approaches — Two Routes to the Same Goal

The distinction between in vivo and ex vivo gene therapy is not merely technical — it reflects fundamentally different relationships between the patient, the vector, and the target cells, with different safety profiles, manufacturing requirements, and clinical logistics.

Gene Addition and Augmentation — Replacing What Is Missing

Gene addition — delivering a functional copy of a defective or absent gene to restore lost protein function — is the most conceptually straightforward and clinically most established gene therapy strategy. It requires no knowledge of the exact mutation in the patient’s genome, only that the deficient protein’s function can be restored by delivering a functional gene. Its clinical track record, anchored by the approved AAV therapies for haemophilia and retinal dystrophy, is now substantial.

Gene Silencing — RNA Interference and Antisense Oligonucleotides

Not all gene therapy targets involve restoring a missing function — many disease-relevant genes are overactive, mutated in a dominant gain-of-function manner, or produce a harmful protein that needs to be reduced or eliminated. Gene silencing approaches target the mRNA or gene expression machinery rather than the genomic DNA, offering potentially reversible and adjustable modulation of gene expression without permanent genomic alteration.

CRISPR-Cas9 — Programmable Genome Editing at Single-Nucleotide Resolution

CRISPR-Cas9 represents the most significant technological shift in gene therapy since the development of recombinant viral vectors. It provides a programmable, RNA-guided nuclease system that can be directed to virtually any genomic sequence with a specificity determined by a 20-nucleotide guide RNA — enabling gene disruption, correction, and insertion at specific genomic loci with a precision and accessibility that previous editing tools (zinc finger nucleases, TALENs) could not match at reasonable cost and development time.

CRISPR-Cas9 MECHANISM:
1. Guide RNA (gRNA) = crRNA + tracrRNA (or single guide RNA — sgRNA)
2. sgRNA base-pairs with 20 nt target sequence in genomic DNA
3. PAM sequence (NGG for SpCas9) 3' of target is required for Cas9 binding
4. Cas9 introduces blunt double-strand break (DSB) 3 bp upstream of PAM

DSB REPAIR PATHWAY 1 — NHEJ (Non-Homologous End Joining):
Dominant pathway in most cell types
→ Error-prone ligation: insertions and deletions (indels) at cut site
→ Frameshift mutations → premature stop codon → loss of protein function
USE CASE: Gene disruption/silencing; disruption of BCL11A to reactivate HbF (Casgevy)

DSB REPAIR PATHWAY 2 — HDR (Homology-Directed Repair):
Active primarily in S/G2 phase of dividing cells
→ Uses provided DNA template: corrects mutation precisely or inserts sequence
USE CASE: Gene correction in haemophilia, sickle cell; inserting therapeutic genes at safe harbour loci
LIMITATION: Inefficient in post-mitotic cells; HDR template delivery is complex

OFF-TARGET EDITING — A Key Safety Consideration:
CRISPR can cut at unintended genomic sites with similar sequence to the intended target
Assessment tools: GUIDE-seq, CIRCLE-seq, Digenome-seq, whole-genome sequencing
Minimisation: high-fidelity Cas9 variants (eSpCas9, HiFi Cas9); truncated gRNAs;
carefully selected gRNA sequences avoiding predicted off-target sites

DELIVERY FORMS FOR GENE THERAPY:
Plasmid DNA (transient but genotoxicity risk from prolonged Cas9 expression)
mRNA + gRNA (transient expression — preferred for clinical applications)
Ribonucleoprotein (RNP — Cas9 protein + gRNA complex — most transient, lowest off-target)
AAV (persistent but limited by 4.7 kb capacity for Cas9 + gRNA)

The Nobel Prize in Chemistry 2020 was awarded to Jennifer Doudna and Emmanuelle Charpentier for their foundational work characterising and adapting the CRISPR-Cas9 system — the fastest translation of a fundamental scientific discovery to Nobel recognition in modern chemistry history. The subsequent development of Casgevy — from the 2012 Science papers to first regulatory approval in November 2023 — took just eleven years, an astonishing pace for a fundamentally new therapeutic modality, enabled in part by the coincidence of CRISPR’s development with the existing infrastructure of haematopoietic stem cell transplantation into which CRISPR-based HSC modification fit naturally as an ex vivo approach.

Base Editing and Prime Editing — Precision Without Double-Strand Breaks

CRISPR-Cas9’s mechanism involves a double-strand DNA break — an event that, while enabling powerful editing, activates cellular DNA damage response pathways, can produce chromosomal translocations when multiple cuts are made simultaneously, and is inefficient for HDR in post-mitotic cells. The development of base editing and prime editing addresses these limitations by achieving precise chemical alterations at specific genomic sites without introducing double-strand breaks.

RNA Therapeutics — Modulating Gene Expression Without Editing DNA

RNA therapeutics represent a distinct conceptual approach within the gene therapy spectrum — rather than altering genomic DNA permanently or semi-permanently, they act at the RNA level to modulate gene expression in a dose-dependent, potentially reversible manner. The distinction between RNA therapeutics and traditional small-molecule drugs is that RNA-based medicines act through nucleic acid base-pairing interactions rather than protein binding, allowing them to be designed computationally against virtually any mRNA target once the sequence is known.

CAR-T Cell Therapy — Engineering Immunity Against Cancer

CAR-T cell therapy is the most commercially successful form of ex vivo gene therapy — by volume of patients treated and cumulative revenue, it represents the leading edge of the gene therapy market. It illustrates the power of combining gene engineering with cellular therapy: using genetic modification to give the immune system targeting capabilities it does not naturally possess against cancer cells that have evolved to evade normal immune recognition.

Approved Gene Therapies — What Has Reached Patients

The approved gene therapy landscape has expanded substantially since 2017, reflecting both the maturation of AAV platform technology and the accumulation of long-term safety data from pioneering trials. Each approved product represents a specific disease, vector, and clinical approach — together they illustrate the breadth of the field and the diversity of conditions now amenable to genetic treatment.

Safety Challenges — Immunology, Genotoxicity, and Dose

The safety profile of gene therapy is distinct from both small-molecule drugs and biologics — it combines the immunological challenges of protein therapeutics with the genotoxic risks of genomic integration and the unprecedented delivery dynamics of engineered viruses. Each modality carries its own specific risk profile, and the current clinical frameworks reflect hard-won knowledge from adverse events in early trials.

Somatic vs Germline Gene Therapy — The Ethical Divide

The distinction between somatic and germline gene therapy is the most ethically consequential divide in genetic medicine — separating interventions whose effects are confined to the treated individual from those whose effects would be inherited by all future descendants. This distinction is not merely technical; it is the boundary between medicine that affects one person and medicine that affects the entire human germline, permanently altering heritable genetic material that has accumulated through billions of years of evolution.

Regulatory Frameworks — How Gene Therapies Are Approved

Gene therapies are regulated as biological medicines in most jurisdictions — their regulatory pathway shares features with biologics and medical devices while incorporating gene therapy-specific requirements for genotoxicity, long-term safety follow-up, vector characterisation, and manufacturing quality standards. The regulatory frameworks reflect the field’s specific risk profile and the hard lessons of adverse events in early trials.

In the United States, the FDA’s Center for Biologics Evaluation and Research (CBER) regulates gene therapy products under biological licence applications (BLAs). The FDA’s 2020 guidance documents for human gene therapy — covering long-term follow-up, manufacturing, and specific disease categories including haematology and ophthalmology — formalised many requirements that had evolved through advisory committee recommendations. In Europe, the EMA’s Committee for Advanced Therapies (CAT) evaluates Advanced Therapy Medicinal Products (ATMPs), a category that includes gene therapies, cell therapies, and tissue-engineered products. ATMP regulation in Europe has been challenging — the centralised approval process has faced delays that have led some companies to pursue FDA approval first. The FDA’s gene therapy regulatory portal provides public access to guidance documents, advisory committee transcripts, and approved product information for students and researchers accessing the regulatory science literature.

Emerging Directions — Where Gene Therapy Is Heading

The gene therapy field is undergoing several simultaneous transitions that together suggest the next decade will see more approved products than the preceding thirty years combined, applications extending well beyond rare monogenic diseases, and delivery technologies that address current limitations of vector biology.

The convergence of CRISPR and next-generation editing precision, improved non-viral delivery platforms post-COVID LNP development, expanded manufacturing capacity, and a regulatory framework now sufficiently mature to handle complex genetic products positions gene therapy to move from the rare disease specialty into mainstream medicine. Students working on biology assignments, research papers, or literature reviews in this space will find that keeping up with the pace of development — a new approval, a pivotal trial result, a new delivery platform — is as challenging as understanding the underlying science. Our guide to challenging research topics offers practical framing strategies for navigating rapidly evolving scientific fields in academic writing.

Frequently Asked Questions About Gene Therapy